Key result
SGLT2 inhibitors reduce arterial stiffness and improve endothelial function in T2D by preserving eNOS activity.
Why the study?
While SGLT2 inhibitors provide robust cardioprotection in type 2 diabetes mellitus, whether these benefits stem from direct vascular effects or from secondary systemic hemodynamics remains an active translational question.
Do sodium-glucose co-transporter 2 inhibitors improve endothelial function and vascular restoration in type 2 diabetes mellitus?
Do sodium-glucose co-transporter 2 inhibitors improve endothelial function and vascular restoration in type 2 diabetes mellitus?
This review summarizes the cellular mechanisms and clinical vascular correlates of SGLT2 inhibitors in protecting endothelial function in type 2 diabetes mellitus, while noting confounding by systemic hemodynamic and metabolic effects.
May support direct SGLT2i vascular effects in T2DM; leaves open translation to clinical outcomes beyond hemodynamics.
Endothelial dysfunction is a fundamental catalyst of atherosclerosis and cardiovascular mortality in type 2 diabetes mellitus (T2DM). While sodium-glucose co-transporter 2 inhibitors (SGLT2is) provide robust cardioprotection, whether these benefits stem from direct vasculature effects or from secondary systemic hemodynamics remains an active translational frontier. At the cellular level, preclinical data suggests that SGLT2is may modulate homeostatic pathways by suppressing NADPH oxidase-mediated oxidative stress, attenuating NF-κB/NLRP3-driven inflammatory cascades, and preserving endothelial nitric oxide synthase (eNOS) activity. In clinical cohorts, these molecular actions correlate with heterogeneous changes in flow-mediated dilation (FMD) and reductions in arterial stiffness. However, translating these cellular findings to macrovascular outcomes is highly confounded by concurrent volume contraction, blood pressure lowering and metabolic shifts.
No takes yet. Share an insight, caveat, or question.
Okojie et al. (2026) conducted a review in Type 2 diabetes mellitus and endothelial dysfunction. Sodium-glucose co-transporter 2 inhibitors (SGLT2is) was evaluated. SGLT2 inhibitors suppress oxidative stress and inflammation to preserve eNOS activity, correlating with reduced arterial stiffness and heterogeneous flow-mediated dilation changes in T2DM.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: